Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma Strengthens Executive Team With Appointments of Chief Medical Officer and Senior Director of Clinical Operations
Experienced Clinical Executives to Drive Phase 3 Trial of EVK-001 for Gastroparesis
View HTML
Toggle Summary Evoke Pharma Selects SynteractHCR as Contract Research Organization for Phase 3 Trial of EVK-001 for Gastroparesis
SAN DIEGO , Nov. 26, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the selection of SynteractHCR, Inc. to serve as its primary contract research organization ("CRO") for its
View HTML
Toggle Summary Evoke Pharma Reports Third Quarter 2013 Results
SAN DIEGO , Nov. 13, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2013 .
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2013 Financial Results
SAN DIEGO , Nov. 5, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Third Quarter of 2013 on Wednesday, November 13, 2013 , after
View HTML
Toggle Summary Evoke Pharma Announces Full Exercise of Underwriters' Over-Allotment Option
SAN DIEGO , Oct. 3, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the full exercise of the over-allotment option granted to the representative of the underwriters to purchase an
View HTML
Toggle Summary Evoke Pharma Announces Closing of Initial Public Offering of 2,100,000 Shares of Common Stock
SAN DIEGO , Sept. 30, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the closing of its previously announced initial public offering of common stock.
View HTML
Toggle Summary Evoke Pharma Announces Pricing of Initial Public Offering of 2,100,000 Shares of Common Stock
SAN DIEGO, CA, September 24, 2013 – Evoke Pharma, Inc., a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the pricing of its initial public offering of 2,100,000 shares of its common stock at a public offering price of $12.00 per
View HTML